AstraZeneca files 2025 Form 20-F with SEC

AstraZeneca PLC has filed its 2025 Annual Report on Form 20-F with the US Securities and Exchange Commission.

Rhea-AI Filing Summary

AstraZeneca PLC has filed its 2025 Annual Report on Form 20-F with the US Securities and Exchange Commission. The report can be viewed on both the SEC website and the company’s own site, giving investors access to detailed audited financial and business information.

The company will provide any security holder with a hard copy of its complete audited financial statements free of charge upon request through its Company Secretary in Cambridge, UK.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did AstraZeneca (AZN) announce in this Form 6-K?

AstraZeneca announced it has filed its 2025 Annual Report on Form 20-F with the US Securities and Exchange Commission, making the full audited report available on both the SEC and company websites for investor review.

Where can investors access AstraZeneca’s 2025 Form 20-F?

Investors can access AstraZeneca’s 2025 Form 20-F on the US SEC website at www.sec.gov and on the company’s own website at www.astrazeneca.com, ensuring broad and convenient digital access to the annual report.

Can AstraZeneca (AZN) shareholders get a hard copy of the annual financial statements?

Yes, AstraZeneca will send any holder of its securities a hard copy of the complete audited financial statements free of charge, if requested in writing from the Company Secretary at the company’s Cambridge, UK address.

What type of company is AstraZeneca (AZN) as described in the notice?

AstraZeneca is described as a global, science-led biopharmaceutical company focused on prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology, with products sold in more than 125 countries.

Which stock exchanges list AstraZeneca (AZN)?

The notice states that AstraZeneca is listed on the London Stock Exchange (LSE), Nasdaq Stockholm (STO), and the New York Stock Exchange (NYSE), reflecting its presence across major European and US equity markets.

Who signed the AstraZeneca Form 6-K related to the Form 20-F filing?

The report was signed on behalf of AstraZeneca PLC by Matthew Bowden, the Company Secretary, confirming that an authorized senior officer validated the submission under the requirements of the US Securities Exchange Act of 1934.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/25/2026 - 10:40 AM EST Learn about SEC filing dates

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the month of February 2026

Commission File Number: 001-11960

AstraZeneca PLC

1 Francis Crick Avenue

Cambridge Biomedical Campus

Cambridge CB2 0AA

United Kingdom

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F X      Form 40-F __

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes __      No X

If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________

AstraZeneca PLC

INDEX TO EXHIBITS

1.

Filing of Form 20-F with SEC

25 February 2026

Filing of Annual Report on Form 20-F with the US Securities and Exchange Commission

AstraZeneca PLC (the Company) announced today that, on 24 February 2026, it filed its 2025 Annual Report on Form 20-F with the US Securities and Exchange Commission (SEC). The document is available for viewing on the SEC website at www.sec.gov and also on the Company's website at www.astrazeneca.com. The Company will send any holder of the Company's securities, upon request, a hard copy of the Company's complete audited financial statements free of charge. Requests may be made by writing to the Company Secretary, AstraZeneca PLC, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA, UK.

AstraZeneca

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Social Media @AstraZeneca.

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

Matthew Bowden

Company Secretary

AstraZeneca PLC

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date: 25 February 2026

By: /s/ Matthew Bowden

Name: Matthew Bowden

Title: Company Secretary